Create account to read this article for free
Get free access to a limited number of articles.
Deep Apple and Novo Nordisk in collaboration on oral drugs
Deep Apple Therapeutics has entered into a research and licensing agreement with Novo Nordisk to discover, develop and commercialize oral small molecule drugs targeting a novel non-incretin GPCR target for cardiometabolic diseases, including...
Notes
Alvotech acquires Ivers-Lee Group in Switzerland
OncoZenge enters into convertible loan with Linc
Merck close to buying Verona Pharma for USD 10 billion
Acarix takes first order in the MENA region
Modus Therapeutics completes recruitment in Phase IIa study
NEWSLETTER
NEWS
The new era of weight loss: Does GLP-1 live up to expectations?
Trump threatens 200 percent tariffs on pharmaceuticals
New announcement from Japan strengthens Medivir's patent portfolio
Upcoming events!
Investing in Life Science
Discover unparalleled opportunities, set in the vibrant heart of Stockholm. This premier event unites forward-thinking investors and business leaders to...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Chronicles
The EU's new life science strategy – a step in the right direction or just fluff?
Early signs of spring in an otherwise frosty biotech landscape
